Corrections or additions?

This article by Barbara Fox was prepared for the May 8, 2002

edition of

U.S. 1 Newspaper. All rights reserved.

Geneva Expands

Apparently following a strategy to transfer many of

its operations to the East Coast of the United States, a Swiss

pharmaceutical

company, Novartis, has moved the headquarters of its generic company

from Colorado to Princeton, and next month it will complete the move

with an expansion. Novartis’ Geneva Pharmaceuticals is moving seventy

people from the Enterprise Business Center (Morgan Lane) to 506

Carnegie

Center.

"We are one of the top five generic companies in the United

States,"

says Oliver Esman, Geneva’s vice president of human resources,

"and

we manufacture a wide range of generic products."

"It is a wonderful labor market here, not only in technical

knowledge

but in range of pharmaceutical and nonpharmaceutical people we have

been able to attract," says Esman. "We have hired an

accounting

group and some HR people, and we brought our sales and marketing

teams."

Based in Basel, Switzerland, Novartis has just announced it will move

its command center for global research from Basel to Cambridge,

Massachusetts,

where it will establish a center for genetic research. According to

the Wall Street Journal (May 7), the move represents "one of the

most significant defections yet from Europe’s once-might

pharmaceuticals

industry in favor of the U.S., now the world’s largest and most

lucrative

pharmaceuticals market."

Novartis’ North American administrative headquarters is in East

Hanover.

Its generic company, Geneva, is based in Kundl, Austria, and now the

North American headquarters will be at the Carnegie Center. The R&D

center, the former Invamed facility, will remain on Route 130 in

Dayton.

Colorado will retain its manufacturing, distribution, and logistics

facilities in Broomfield, a suburb of Denver.

"The heart of the pharmaceutical industry, in terms of management,

is in north Jersey," says Esman, "and more of our customers

are on the East Coast." Esman grew up in Pittsburgh and graduated

from Cornell in 1974. He came to Geneva last fall from a similar

position

at another generic company, Schein Pharma in north Jersey.

Geneva’s CEO John Sedor (pronounced Seedor) joined the company last

year. He had worked in Pennsylvania for Rhone Poulenc Rorer and its

predecessors. A graduate of Pittsburgh’s Duquesne University (Class

of 1970) he has also been at Centeon in King of Prussia. His most

recent job was with Verion, an Exton, Pennsylvania startup that works

on microencapsulation technology.

A mid to late June move is planned.

Geneva Pharmaceuticals (ADR), 101 Morgan Lane,

Suite 200, Plainsboro 08536. John Sedor, CEO. 609-750-4734; fax,

609-750-4797.

Www.genevarx.com


Previous Story Next Story


Corrections or additions?


This page is published by PrincetonInfo.com

— the web site for U.S. 1 Newspaper in Princeton, New Jersey.

Facebook Comments